Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

SA Transcripts
153.96K Followers

Q3: 2024-11-08 Earnings Summary

EPS of $0.16 beats by $0.02
 | Revenue of $702.47M (13.29% Y/Y) beats by $8.74M

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET

Company Participants

Tony DiMeo - Head of Investor Relations
Chirag Patel - President & Co-Chief Executive Officer
Chintu Patel - Co-Chief Executive Officer
Tasos Konidaris - Executive Vice President & Chief Financial Officer
Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty

Conference Call Participants

David Amsellem - Piper Sandler
Balaji Prasad - Barclays Bank
Leszek Sulewski - Truist Securities
Chris Schott - JPMorgan

Operator

Hello, everyone and thank you for your patience. The Amneal Pharmaceuticals Third Quarter 2024 Earnings Call will begin shortly. [Operator Instructions] Thank you. Good morning and welcome to the Amneal Pharmaceuticals Third Quarter 2024 Earnings Call.

I'd now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. Please go ahead.

Tony DiMeo

Good morning and thank you for joining Amneal Pharmaceuticals' third quarter 2024 earnings call.

Today, we issued a press release reporting Q3 results. The earnings press release and presentation are available at amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to, management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation.

On the call today are Chirag and Chintu Patel, co-Founders and co-CEOs, Tasos Konidaris, CFO; our commercial leaders, Andy Boyer for Generics; Joe Renda Specialty; and Jason Daly, Chief Legal Officer.

I will now hand the call over to Chirag.

Chirag Patel

Thank you, Tony. Good morning to everyone. We're excited to talk about our strong Q3

Recommended For You

About AMRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AMRX